Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Melanoma 31Neoplasms 17Multiple Myeloma 9Thyroid Neoplasms 8Hematologic Neoplasms 7Thyroid Carcinoma, Anaplastic 6Carcinoma, Non-Small-Cell Lung 6Brain Neoplasms 6Lymphoma 5Glioma 5Colorectal Neoplasms 5Thyroid Cancer, Papillary 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Neurofibromatosis 1 3Leukemia, Myeloid, Acute 3Biliary Tract Neoplasms 3Astrocytoma 3Adenocarcinoma, Follicular 3Uveal Melanoma 2Uterine Cervical Neoplasms 2Skin Neoplasms 2Neurofibroma, Plexiform 2Neoplasm Metastasis 2Glioblastoma 2Gastrointestinal Stromal Tumors 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Hepatocellular 2Breast Neoplasms 2

Interventions

trametinib 2dabrafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Ameloblastoma × trametinib × Clear all
NCT06653517 2024-10-22

NETCAM

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Phase 2 Recruiting
12 enrolled

Ameloblastoma

NCT02367859 2024-01-30

Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma

Stanford University

Phase 2 Completed
1 enrolled 5 charts

Ameloblastoma, Adamantinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡